This is a working overview of ipamorelin, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-21. Anything still debated is marked as such rather than presented as settled.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentapeptide | Chain of five amino acid residues |
| Molecular mass | Approximately 712 Da | Consistent with a five-residue chain |
| Receptor target | GHS-R1a | Growth hormone secretagogue receptor |
| Primary action | Growth hormone release | Pituitary somatotroph stimulation |
| Research origin | Developed in the 1990s | Small-peptide secretagogue program |
现有文献多来自小规模、短期的研究，涉及生长激素缺乏、术后肠麻痹等方向。长期使用是否导致受体脱敏，以及重复给药后效应是否衰减，仍属开放问题。不同研究之间的剂量、给药途径和受试者特征差异较大，因此结论外推需谨慎。关于临床获益的确切证据尚不充分，需要更大规模的对照试验来澄清。
Ipamorelin 是一种合成五肽，在 20 世纪 90 年代被报道为生长激素促分泌剂。其结构基于胃饥饿素受体激动剂的设计思路，但并非天然激素。早期药理学研究显示，它可刺激垂体释放生长激素，而对应激激素轴的影响相对较小。该化合物常被用作研究生长激素调节通路的工具分子。
在机制层面，ipamorelin 与生长激素促分泌受体 1a 型结合，该受体也介导胃饥饿素的多种效应。受体激活后，细胞内信号促进生长激素从垂体前叶释放。由于对促肾上腺皮质激素和皮质醇的刺激较弱，它被视为选择性较高的促分泌剂。这种选择性在动物模型和少量人体研究中被观察到，但人体数据仍然有限。
Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.
Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.
Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.
==== Top-fed deep water culture ==== Top-fed deep water culture is a technique involving delivering highly oxygenated nutrient solution direct to the root zone of plants. While deep water culture involves the plant roots hanging down into a reservoir of nutrient solution, in top-fed deep water culture the solution is pumped from the reservoir up to the roots (top feeding). The water is released over the plant's roots and then runs back into the reservoir below in a constantly recirculating system. As with deep water culture, there is an airstone in the reservoir that pumps air into the water via a hose from outside the reservoir. The airstone helps add oxygen to the water. Both the airstone and the water pump run 24 hours a day. The biggest advantage of top-fed deep water culture over standard deep water culture is increased growth during the first few weeks. With deep water culture, there is a time when the roots have not reached the water yet. With top-fed deep water culture, the roots get easy access to water from the beginning and will grow to the reservoir below much more quickly than with a deep water culture system. Once the roots have reached the reservoir below, there is not a huge advantage with top-fed deep water culture over standard deep water culture. However, due to the quicker growth in the beginning, grow time can be reduced by a few weeks.
== Ligands and potential ligand-based disease related activities == The functions of FPR3 and the few ligands which activate it have not been fully clarified. Despite its homology to FPR1, FPR3 is unresponsive to many FPR1-stimulating formyl peptides including FMLP. However, fMMYALF, a N-formyl hexapeptide derived from the mitochondrial protein, NADH dehydrogenase subunit 6, is a weak agonist for FPR3 but >100-fold more potent in stimulating FPR1 and FPR2. F2L is a naturally occurring acylated peptide derived from the N-terminal sequence of heme-binding protein 1 by cathepsin D cleavage that potently stimulates chemotaxis through FPR3 in monocytes and monocyte-derived dendritic cells. F2L thereby may be a pro-inflammatory stimulus for FPR3. Similar to FPR2 (see FPR2 section), FPR3 is activated by humanin and thereby may be involved in inhibiting the inflammation occurring in and perhaps contributing to Alzheimer's disease.
Bimatoprost may be used to treat small or underdeveloped eyelashes. The medical term for this is treatment of hypotrichosis; however, the U.S. Food and Drug Administration (FDA) approval is for purely cosmetic purposes (see Prostaglandin F receptor#Clinical significance).
Actifed (made by GlaxoSmithKline) — contains 60 mg pseudoephedrine and 2.5 mg triprolidine in certain countries. Advil Cold & Sinus (made by Pfizer Canada Inc.) — contains 30 mg pseudoephedrine hydrochloride (also 200 mg ibuprofen). Aleve-D Sinus & Cold (made by Bayer Healthcare) — contains 120 mg pseudoephedrine hydrochloride (also 220 mg naproxen). Allegra-D (made by Sanofi Aventis) — contains 120 mg of pseudoephedrine hydrochloride (also 60 mg of fexofenadine). Allerclear-D (made by Kirkland Signature) — contains 240 mg of pseudoephedrine sulfate (also 10 mg of loratadine). Benadryl Allergy Relief Plus Decongestant (made by McNeil Consumer Healthcare, a Kenvue company) — contains 60 mg pseudoephedrine hydrochloride (also 8 mg acrivastine) Cirrus (made by UCB) — contains 120 mg pseudoephedrine hydrochloride (also 5 mg cetirizine). Claritin-D (made by Bayer Healthcare) — contains 120 mg of pseudoephedrine sulfate (also 5 mg of loratadine). Claritin-D 24 Hour (made by Bayer Healthcare) — contains 240 mg of pseudoephedrine sulfate (also 10 mg of loratadine). Codral (made by Asia-Pacific subsidiary of Johnson & Johnson) — Codral Original contains pseudoephedrine, Codral New Formula substitutes phenylephrine for pseudoephedrine. Congestal (made by SIGMA Pharmaceutical Industries) — contains 60 mg pseudoephedrine hydrochloride (also 650 mg paracetamol and 4 mg chlorpheniramine). Contac (made by GlaxoSmithKline) — previously contained pseudoephedrine, now contains phenylephrine. As at Nov 2014 UK version still contains 30 mg pseudoephedrine hydrochloride per tablet.
=== Recent history === Since 2002, Bendix has been a subsidiary of Knorr-Bremse. In February 2020, Bendix announced that it would be moving its headquarters from Elyria, Ohio to Avon, Ohio, with an expected opening date for its new facility of November 2021.
Sources: en.wikipedia.org
== Occurrence == Traces of californium can be found near facilities that use the element in mineral prospecting and in medical treatments. The element is fairly insoluble in water, but it adheres well to ordinary soil; and concentrations of it in the soil can be 500 times higher than in the water surrounding the soil particles. Nuclear fallout from atmospheric nuclear weapons testing prior to 1980 contributed a small amount of californium to the environment. Californium-249, -252, -253, and -254 have been observed in the radioactive dust collected from the air after a nuclear explosion. Californium is not a major radionuclide at United States Department of Energy legacy sites since it was not produced in large quantities. Californium was once believed to be produced in supernovas, as their decay matches the 60-day half-life of 254Cf. However, subsequent studies failed to demonstrate any californium spectra, and supernova light curves are now thought to follow the decay of nickel-56. The transuranic elements up to fermium, including californium, should have been present in the natural nuclear fission reactor at Oklo, but any quantities produced then would have long since decayed away.
== Adverse effects == Common side effects include low blood sugar, problems at the site of injection, itchiness, and weight gain. Serious side effects include low blood potassium. As of 2012, tentative evidence shows no association between insulin glargine and cancer. Previous studies had raised concerns. When comparing insulin glargine to NPH insulin, insulin detemir or insulin degludec, no significant adverse effects were found in the management of type 1 diabetes in either adults or children in periods of six months or longer.
==== 2009 ==== In January 2009, Krasnaya Zvezda published an interview with Father Mikhail, the Orthodox priest, who said: "I attended military exercise "Kavkaz-2008" in South Ossetia, where our paratroopers worked out the skills of combat in the mountains. Unfortunately, those skills became useful too soon..." In late January 2009, Russian sergeant Aleksandr Glukhov ran away from Akhalgori District and requested a political asylum in Tbilisi. He had served in the 693rd regiment and he declared that he was deployed to South Ossetia in July 2008. In May 2009, Rossiyskaya Gazeta reported that hero of Russia, Denis Vetchinov, who died in South Ossetia, left the base of the Motor Rifle Division in Vladikavkaz for Tskhinvali on the early morning of 7 August 2008. In June 2009, Russian General Vyacheslav Borisov told Echo of Moscow in an interview: "I headed the South Ossetian and the Georgian directions. You know, we even regularly hold exercises in those areas. And our troops had full practice by holding exercises one week before right there in the same place. And we had only concluded and went." In July 2009, Russian journalist Ella Polyakova wrote that some Russian soldiers had told her that they arrived in South Ossetia on 4 August 2008, while their records claimed that they were stationed in North Ossetia. In July 2009, Russian blogger published an interview with soldier Maksim Belyaev, who said: "Our combined battalion of peacekeepers was stationed in North Ossetia. We should have replaced in August another battalion of the peacekeeping mission, located in Tskhinvali.
James L. Winkle College of Pharmacy Linder College of Business - Masters in Business Administration College of Allied Health - Masters in Health Administration The programs are organized as preparation for leadership in settings such as independent and chain community pharmacies, health-system inpatient, outpatient and clinical pharmacies, clinical coordinator roles, managed care, industry, long-term care.
Matrix-assisted laser desorption ionization can be used as a mass spectrometry imaging technique for relatively large molecules. It has recently been shown that the most effective type of matrix to use is an ionic matrix for MALDI imaging of tissue. In this version of the technique the sample, typically a thin tissue section, is moved in two dimensions while the mass spectrum is recorded. Although MALDI has the benefit of being able to record the spatial distribution of larger molecules, it comes at the cost of lower resolution than the SIMS technique. The limit for the lateral resolution for most of the modern instruments using MALDI is 20
Sources: en.wikipedia.org
=== Generic names === Methylestradiol has not been assigned an INNTooltip International Nonproprietary Name or other formal name designations. Its generic name in English and German is methylestradiol, in French is méthylestradiol, and in Spanish is metilestadiol. It is also known as 17α-methylestradiol.
==== Absorption ==== Enobosarm is orally bioavailable due to a lack of extensive first-pass metabolism. In rats, the oral bioavailability of enobosarm was found to be 100%. Enobosarm is rapidly absorbed with oral administration and reaches maximal concentrations median 1.0 hours (range 1.0–2.0 hours) following administration. The drug reaches a peak concentration of 56.0 ng/mL (range 53.1–123.0 ng/mL) following a single 3 mg dose and a steady-state peak of 68.1 ng/mL following repeated 3 mg doses. The pharmacokinetics of enobosarm are linear and proportional over a dose range of 1 to 100 mg in single doses in healthy men. The pharmacokinetics of enobosarm are similar in young versus elderly individuals. A concentration–time curve of enobosarm levels following a single oral dose of enobosarm in humans has been published.
1967: Sue Arnold became the first female British Geological Survey person to go to sea on a research vessel. 1967: South African radiobiologist Tikvah Alper discovered that scrapie, an infectious brain disease affecting sheep, did not spread via DNA or RNA like a viral or bacterial disease. The discovery enabled scientists to better understand diseases caused by prions. 1967: Yvonne Brill, a Canadian-American rocket and jet propulsion engineer, invented the hydrazine resistojet propulsion system. 1968: Japanese pioneer of molecular biology Tsuneko Okazaki studied DNA replication and discovered Okazaki fragments. 1969: British biostratigrapher Beris Cox became the first female paleontologist in the British Geological Survey. 1969: British botanist Irene Manton became the first woman president of the British Pteridological Society. 1969: Ukrainian-born astronomer Svetlana Gerasimenko co-discovered the 67P/Churyumov–Gerasimenko comet. 1969: A group of women scientists from the United States (Lois Jones, Terry Tickhill, Kay Lindsay, Eileen McSaveney, and Jean Pearson) and New Zealand (Pamela Young) become the first women to visit and work at the South Pole.
The second most common form of SCID after X-SCID is caused by a defective enzyme, adenosine deaminase (ADA), necessary for the breakdown of purines. Lack of ADA causes accumulation of dATP. This metabolite will inhibit the activity of ribonucleotide reductase, the enzyme that reduces ribonucleotides to generate deoxyribonucleotides. The effectiveness of the immune system depends upon lymphocyte proliferation and hence dNTP synthesis. Without functional ribonucleotide reductase, lymphocyte proliferation is inhibited and the immune system is compromised.
Sources: en.wikipedia.org
It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.
In animal studies it showed greater selectivity for growth hormone release, with less effect on cortisol and adrenocorticotropic hormone than compounds such as GHRP-6. This selectivity is one of the most frequently cited features in preclinical literature. Whether the same profile applies in other contexts is not fully established.
The receptor-level events are reasonably well described, but the full range of downstream effects is not. Studies have reported activity in tissues beyond the pituitary, including the gut. How these observations translate across species and conditions remains an open question.
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.